Given the prevalence of activation of the PI3K/mTOR axis and BRAF V600E mutations in pediatric tumors, we designed a pre-clinical study to determine whether inhibitors of mTOR and of BRAF V600E cooperate to enhance cytotoxicity specifically in pediatric low-grade gliomas. Here, BRAF is linked to central nervous system cancer.